Prof. Dr. Peter Brossart
Medical Clinic III for Haematology and Oncology
peter.brossart@ukbonn.de View member: Prof. Dr. Peter Brossart
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
OBJECTIVES: Fever during high-risk neutropenia in patients with hematological malignancies is considered an emergency. Sex and gender differences were described in patients with infectious diseases or cancer, but analyses in patients with high-risk neutropenia are lacking. Here, we present a sex-disaggregated analysis of fever occurrence and underlying causes in a cohort with neutropenia after myelosuppressive chemotherapy for hematological malignancies.
METHODS: We performed a pooled re-analysis of four primary databases collected at two tertiary care centers in Germany between 2001 and 2018. This cohort of high-risk neutropenic patients included 393 women and 513 men.
RESULTS: The overall fever rate was 79% without significant sex differences. In multivariable regression, the duration of neutropenia was the only risk factor for developing fever for women. For men, risk factors were the duration of neutropenia and the age at case and mold-active antifungal prophylaxis was protective. We found significantly higher rates of venous catheter-related infections in men and urinary tract infections in women, before adjusting for multiple testing. Other differences in fever causes were not significant.
CONCLUSIONS: This could point towards a reduced importance of sex-related effects in patients with high-risk neutropenia compared to the severity of the underlying disease and the disease-specific treatment.
Copyright © 2026 The Author(s). Published by Elsevier Ltd.. All rights reserved.
PMID: 42998874
Medical Clinic III for Haematology and Oncology
peter.brossart@ukbonn.de View member: Prof. Dr. Peter Brossart